Advanced Cancer
7 competing products in clinical development for Advanced Cancer.
Pipeline by Phase
Phase 16
Phase 1/21
All Products (7)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| LY3200882 + Pembrolizumab | Eli Lilly | Phase 1/2 | Withdrawn | 41 |
| pegfilgrastim + LY2523355 | Eli Lilly | Phase 1 | Completed | 33 |
| LY3434172 | Eli Lilly | Phase 1 | Terminated | 33 |
| [¹⁴C]Prexasertib + Prexasertib | Eli Lilly | Phase 1 | Completed | 33 |
| AK-105 | Akeso | Phase 1 | Completed | 32 |
| OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib | OnKure Therapeutics | Phase 1 | Recruiting | 25 |
| [14C]-Nanatinostat + Nanatinostat (free base) tablets in combination with Valganciclovir + Nanatinostat mesylate tablets in combination with Valganciclovir + Single-agent Nanatinostat (free base) tablets | Viracta Therapeutics | Phase 1 | Terminated | 25 |